



May 15th 2023

TWSE 4746

2023/5/15

Hope, Passion, Innovation, Sustainability

1



Disclaimer

This material has been prepared by Formosa Laboratories Inc. ("Formosalab").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. Formosalab is under no obligation to update or keep current the information contained herein. The information contained in this presentation is Formosalab's confidential information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to, the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of Formosalab. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other

things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items.

These forwardlooking statements involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.



2023 up-to-April Operation Results


- Business Strategy
- Business Update



Operation Results



2023 Up-to-April Topline Results






2023 Up-to-April Topline Results in Different Categories

	Million NTD	YoY
Polymers	472	27%
Vit. D Derivatives	267	5%
CDMO	155	2%
Respiratory Agents	133	127%
Steroid	23	317%
Total	1,244	11%




Product Category





2022 Profitability

Cash dividend	-0.21	
BP per share	62.33	




*In 2022, the recognized unrealized gains of financial asset 184M *In 2023Q1, the recognized unrealized loss of financial asset 127M 8

2023/5/15




2022-2023Q1Gross Margin Keeps Growing





2023Q1 Gross Margin YoY 62%







Business Strategy



Integrated RD and Manufacturing











Key Business



API Products







Key API Products

- Improve throughput
- Expand manufacture capacity
- Stable supply chain





2022 Highlight

- Polymer products stay strong market share
- Sign long-term supply agreement with European global pharma, expected 80% market share in Europe.
- Sevelamer API approved in China
- Respiratory API sales keeps growing in 2023 up-to-April, YoY 127%
- Steroid 2023 up-to-April YoY 318%, enter originator's supply
- Opportunity to supply to originator
- Vitamin D products keeps growing in 2023 up-to-April, YoY 5%




Comprehensive CDMO Service-One Stop Shop






Comprehensive CDMO Service-One Stop Shop



- Build up alliance to expand US market. A few projects ongoing
- 2 new CDMO projects in 2023 up-to-April (Phase I & Phase III)
- Stable CMO supply to originator in Japan, Europe, and US
- Multiple projects enters validation and/or commercial manufacturing



Once stop ADC services



Service scope

- Process development
- ADC screening platform
- Scale-up
- Comprehensive analytic services
- Formulation development and manufacturing services

ADC CDMO highlight

- Clients includes US, China, Europe, and Taiwan
- Support clients from RD to clinical trial material for Phase I trial.
- New ADC clients is now manufacturing drug substance and drug product to be delivered 2023Q3 for global clinical trial



One stop fermentation manufacturing

- Strains selection, optimization, process development and purification
- 2022Q4 passed FDA on-site inspection without 483
- Commercialized fermentation API products enters US market
- Capability of analytic, formulation, and manufacturing capability to provide one-stop services







Advanced Technology

- Build up peptide synthesis laboratory with automatic solidphase microwave synthesis
- Set up microfluidic reactor scale-up planned in 2023Q4









Injectable Plant Status

- Authority inspection is ongoing
 - Cytotoxic line
 - TFDA: 2022Q2
 - FDA: 2024
 - General line
 - TFDA: 2024
 - FDA: 2025
 - Feasible for biologic and chemical drug
 - Liquid and Lyophilization product
 - Clinical trial and commercial scale








Self-development Injectable Products



Eribulin Injectable (Global market size USD 370 million, US Market USD 130 million, TW market NTD 450 million)

- License-out to Fresenius Kabi in US, Canada, and APAC
- License-out in other territories is expected in 2023
- Licensing-out for other self-development injectable products is ongoing with global pharma







Q & A